RxDoctor Payments Data

Caitlin Colescott

Family · Saint Joseph, MONPI 1114635182

Payments from drug & device makers

$2,265in general payments, 2019–2025

Across 126 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$328
  • AbbVie$307
  • Otsuka America Pharmaceutical, Inc.$286
  • Viiv Healthcare Company$243
  • Vanda Pharmaceuticals Inc.$205
  • Amgen$139
  • plus $757 from 19 others

What the payments were for

  • Food & beverage$2,265100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,265 in reported general payments places this provider in the 80th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$1,933
Medicare patients
43
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol35$27,964
OzempicSemaglutide25$23,332
RexultiBrexpiprazole13$22,100
SymbicortBudesonide/Formoterol Fumarate62$21,568
TrulicityDulaglutide14$17,085
MyrbetriqMirabegron31$16,715
JardianceEmpagliflozin23$15,673
XareltoRivaroxaban16$9,961
EliquisApixaban13$9,954
JanuviaSitagliptin Phosphate15$8,370
Aripiprazole49$6,314
DuleraMometasone/Formoterol13$6,023
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$4,833
Gabapentin278$4,218
Albuterol Sulfate HfaAlbuterol Sulfate126$3,753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$328$49,53297 claims
Novo NordiskOzempic$59$23,33225 claims
Otsuka America Pharmaceutical, Inc.Rexulti$286$22,10013 claims
Lilly USA, LLCTrulicity$117$17,08514 claims
Astellas Pharma US IncMyrbetriq$64$16,71531 claims
Boehringer IngelheimJardiance$14$15,67323 claims
MerckJanuvia, Dulera$18$14,39328 claims
Johnson & JohnsonXarelto$22$9,96116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,812 family providers in Missouri.

Other family in Saint Joseph

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →